The European Patent Office (EPO) has published patent application EP4494655A1, detailing a combination therapy involving a multi-specific molecule and an immune checkpoint inhibitor. The application, filed by Daiichi Sankyo Company, Limited, focuses on novel treatments for cancer, specifically mentioning applications in treating solid tumors and hematological malignancies.

This publication represents a new patent filing and does not impose immediate compliance obligations on regulated entities. However, it is relevant for pharmaceutical companies and drug manufacturers involved in oncology research and development, as it pertains to intellectual property in the field of cancer therapeutics. Companies operating in this space should monitor the patent's prosecution and potential grant for competitive intelligence and freedom-to-operate assessments.